A double blind, randomised, dose finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005-003680-22

C. Parker, R. Hoskin, S. Pascoe, A. Chodack, Joe O'Sullivan, J.R. Germa, A. Lokna

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)406-406
Number of pages1
JournalEJC SUPPLEMENTS
Volume7
Publication statusPublished - Sep 2009

Cite this